ACE Inhibitors for Microalbuminuria in Diabetes

Efficacy of ACE Inhibitors in Diabetic Nephropathy

The American Diabetes Association recommends ACE inhibitors as first-line agents for treating microalbuminuria in both type 1 and type 2 diabetes, with evidence suggesting they delay progression from microalbuminuria to macroalbuminuria 1, 2, 3
ACE inhibitors, including lisinopril and enalapril, work through the same mechanism to reduce intraglomerular pressure and albuminuria, with clinical guidelines suggesting a class effect 1, 2, 3, 4, 5
The American College of Cardiology and other guideline societies support the use of ACE inhibitors for renoprotection in diabetic patients with microalbuminuria, based on high-quality evidence 1, 2, 3

For optimal renoprotection, the American Heart Association recommends titrating ACE inhibitors to the maximum approved dose if tolerated, with regular monitoring of serum creatinine and potassium levels 6, 7
The National Kidney Foundation suggests continuing surveillance of urinary albumin-to-creatinine ratio to assess both response to therapy and disease progression, with a target blood pressure below 130/80 mmHg in patients with diabetes and microalbuminuria 7, 8

Both lisinopril and enalapril can cause hyperkalemia, especially in patients with reduced kidney function, with the American Diabetes Association recommending monitoring for acute increases in serum creatinine 3, 6
The American College of Cardiology advises considering referral to a nephrologist when GFR falls below 60 mL/min/1.73m², with both ACE inhibitors contraindicated in pregnancy 2, 6

If one ACE inhibitor is not tolerated due to side effects, the European Society of Cardiology recommends considering switching to the other ACE inhibitor before changing to an ARB, with avoidance of combination of ACE inhibitors and ARBs due to increased risk of adverse events 1, 2, 6